PETALING JAYA: As the Covid-19 pandemic hype diminishes, Duopharma Biotech Bhd
’s strong execution and consistent earnings growth should eventually lead to a re-rating.
Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
